ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Long Chain Modified Peptide Drugs Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-5S15110
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Long Chain Modified Peptide Drugs Market Research Report 2023
BUY CHAPTERS

Global Long Chain Modified Peptide Drugs Market Research Report 2025

Code: QYRE-Auto-5S15110
Report
May 2025
Pages:83
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Lilly
Astrazeneca plc
SciClone Pharmaceuticals
Sinopep Allsino Bio Pharmaceutical
Roche
Sanofi
lpsen PHarma Biotech
Ambio Pharmaceuticals
Ferring Pharmaceuticals
Merck Serono
Novartis
Takeda

Long Chain Modified Peptide Drugs Market

The global market for Long Chain Modified Peptide Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Long Chain Modified Peptide Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Long Chain Modified Peptide Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Long Chain Modified Peptide Drugs in Intravenous Injection is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Long Chain Modified Peptide Drugs include Novartis, Merck Serono, Ferring Pharmaceuticals, lpsen PHarma Biotech, Lilly, AstraZeneca, SciClone Pharmaceuticals, Sinopep Allsino Bio Pharmaceutical, Takeda, Roche, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Long Chain Modified Peptide Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long Chain Modified Peptide Drugs.
The Long Chain Modified Peptide Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long Chain Modified Peptide Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long Chain Modified Peptide Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Long Chain Modified Peptide Drugs Market Report

Report Metric Details
Report Name Long Chain Modified Peptide Drugs Market
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novartis, Merck Serono, Ferring Pharmaceuticals, lpsen PHarma Biotech, Lilly, AstraZeneca, SciClone Pharmaceuticals, Sinopep Allsino Bio Pharmaceutical, Takeda, Roche, Sanofi, Ambio Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Long Chain Modified Peptide Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Long Chain Modified Peptide Drugs Market report?

Ans: The main players in the Long Chain Modified Peptide Drugs Market are Novartis, Merck Serono, Ferring Pharmaceuticals, lpsen PHarma Biotech, Lilly, AstraZeneca, SciClone Pharmaceuticals, Sinopep Allsino Bio Pharmaceutical, Takeda, Roche, Sanofi, Ambio Pharmaceuticals

What are the Application segmentation covered in the Long Chain Modified Peptide Drugs Market report?

Ans: The Applications covered in the Long Chain Modified Peptide Drugs Market report are Intravenous Injection, Intramuscular Injection, Hypodermic Injection, Others

What are the Type segmentation covered in the Long Chain Modified Peptide Drugs Market report?

Ans: The Types covered in the Long Chain Modified Peptide Drugs Market report are Hormone Peptide Drugs, Immunomodulatory Peptide Drugs, Vasoactive Peptide Drugs, Others

Recommended Reports

Peptide Drug Markets

Drug Delivery Systems

Pharmaceutical Supply Chain

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long Chain Modified Peptide Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Hormone Peptide Drugs
1.2.3 Immunomodulatory Peptide Drugs
1.2.4 Vasoactive Peptide Drugs
1.2.5 Others
1.3 Market by Application
1.3.1 Global Long Chain Modified Peptide Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Intravenous Injection
1.3.3 Intramuscular Injection
1.3.4 Hypodermic Injection
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long Chain Modified Peptide Drugs Market Perspective (2020-2031)
2.2 Global Long Chain Modified Peptide Drugs Growth Trends by Region
2.2.1 Global Long Chain Modified Peptide Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Long Chain Modified Peptide Drugs Historic Market Size by Region (2020-2025)
2.2.3 Long Chain Modified Peptide Drugs Forecasted Market Size by Region (2026-2031)
2.3 Long Chain Modified Peptide Drugs Market Dynamics
2.3.1 Long Chain Modified Peptide Drugs Industry Trends
2.3.2 Long Chain Modified Peptide Drugs Market Drivers
2.3.3 Long Chain Modified Peptide Drugs Market Challenges
2.3.4 Long Chain Modified Peptide Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long Chain Modified Peptide Drugs Players by Revenue
3.1.1 Global Top Long Chain Modified Peptide Drugs Players by Revenue (2020-2025)
3.1.2 Global Long Chain Modified Peptide Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Long Chain Modified Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Long Chain Modified Peptide Drugs Revenue
3.4 Global Long Chain Modified Peptide Drugs Market Concentration Ratio
3.4.1 Global Long Chain Modified Peptide Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long Chain Modified Peptide Drugs Revenue in 2024
3.5 Global Key Players of Long Chain Modified Peptide Drugs Head office and Area Served
3.6 Global Key Players of Long Chain Modified Peptide Drugs, Product and Application
3.7 Global Key Players of Long Chain Modified Peptide Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Long Chain Modified Peptide Drugs Breakdown Data by Type
4.1 Global Long Chain Modified Peptide Drugs Historic Market Size by Type (2020-2025)
4.2 Global Long Chain Modified Peptide Drugs Forecasted Market Size by Type (2026-2031)
5 Long Chain Modified Peptide Drugs Breakdown Data by Application
5.1 Global Long Chain Modified Peptide Drugs Historic Market Size by Application (2020-2025)
5.2 Global Long Chain Modified Peptide Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Long Chain Modified Peptide Drugs Market Size (2020-2031)
6.2 North America Long Chain Modified Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Long Chain Modified Peptide Drugs Market Size by Country (2020-2025)
6.4 North America Long Chain Modified Peptide Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long Chain Modified Peptide Drugs Market Size (2020-2031)
7.2 Europe Long Chain Modified Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Long Chain Modified Peptide Drugs Market Size by Country (2020-2025)
7.4 Europe Long Chain Modified Peptide Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Long Chain Modified Peptide Drugs Market Size (2020-2031)
8.2 Asia-Pacific Long Chain Modified Peptide Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Long Chain Modified Peptide Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Long Chain Modified Peptide Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Long Chain Modified Peptide Drugs Market Size (2020-2031)
9.2 Latin America Long Chain Modified Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Long Chain Modified Peptide Drugs Market Size by Country (2020-2025)
9.4 Latin America Long Chain Modified Peptide Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long Chain Modified Peptide Drugs Market Size (2020-2031)
10.2 Middle East & Africa Long Chain Modified Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Long Chain Modified Peptide Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Long Chain Modified Peptide Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Long Chain Modified Peptide Drugs Introduction
11.1.4 Novartis Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.1.5 Novartis Recent Development
11.2 Merck Serono
11.2.1 Merck Serono Company Details
11.2.2 Merck Serono Business Overview
11.2.3 Merck Serono Long Chain Modified Peptide Drugs Introduction
11.2.4 Merck Serono Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.2.5 Merck Serono Recent Development
11.3 Ferring Pharmaceuticals
11.3.1 Ferring Pharmaceuticals Company Details
11.3.2 Ferring Pharmaceuticals Business Overview
11.3.3 Ferring Pharmaceuticals Long Chain Modified Peptide Drugs Introduction
11.3.4 Ferring Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.3.5 Ferring Pharmaceuticals Recent Development
11.4 lpsen PHarma Biotech
11.4.1 lpsen PHarma Biotech Company Details
11.4.2 lpsen PHarma Biotech Business Overview
11.4.3 lpsen PHarma Biotech Long Chain Modified Peptide Drugs Introduction
11.4.4 lpsen PHarma Biotech Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.4.5 lpsen PHarma Biotech Recent Development
11.5 Lilly
11.5.1 Lilly Company Details
11.5.2 Lilly Business Overview
11.5.3 Lilly Long Chain Modified Peptide Drugs Introduction
11.5.4 Lilly Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.5.5 Lilly Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Details
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Long Chain Modified Peptide Drugs Introduction
11.6.4 AstraZeneca Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.6.5 AstraZeneca Recent Development
11.7 SciClone Pharmaceuticals
11.7.1 SciClone Pharmaceuticals Company Details
11.7.2 SciClone Pharmaceuticals Business Overview
11.7.3 SciClone Pharmaceuticals Long Chain Modified Peptide Drugs Introduction
11.7.4 SciClone Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.7.5 SciClone Pharmaceuticals Recent Development
11.8 Sinopep Allsino Bio Pharmaceutical
11.8.1 Sinopep Allsino Bio Pharmaceutical Company Details
11.8.2 Sinopep Allsino Bio Pharmaceutical Business Overview
11.8.3 Sinopep Allsino Bio Pharmaceutical Long Chain Modified Peptide Drugs Introduction
11.8.4 Sinopep Allsino Bio Pharmaceutical Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.8.5 Sinopep Allsino Bio Pharmaceutical Recent Development
11.9 Takeda
11.9.1 Takeda Company Details
11.9.2 Takeda Business Overview
11.9.3 Takeda Long Chain Modified Peptide Drugs Introduction
11.9.4 Takeda Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.9.5 Takeda Recent Development
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche Long Chain Modified Peptide Drugs Introduction
11.10.4 Roche Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.10.5 Roche Recent Development
11.11 Sanofi
11.11.1 Sanofi Company Details
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Long Chain Modified Peptide Drugs Introduction
11.11.4 Sanofi Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.11.5 Sanofi Recent Development
11.12 Ambio Pharmaceuticals
11.12.1 Ambio Pharmaceuticals Company Details
11.12.2 Ambio Pharmaceuticals Business Overview
11.12.3 Ambio Pharmaceuticals Long Chain Modified Peptide Drugs Introduction
11.12.4 Ambio Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025)
11.12.5 Ambio Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Lilly
Astrazeneca plc
SciClone Pharmaceuticals
Sinopep Allsino Bio Pharmaceutical
Roche
Sanofi
lpsen PHarma Biotech
Ambio Pharmaceuticals
Ferring Pharmaceuticals
Merck Serono
Novartis
Takeda
List of Tables
 Table 1. Global Long Chain Modified Peptide Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Hormone Peptide Drugs
 Table 3. Key Players of Immunomodulatory Peptide Drugs
 Table 4. Key Players of Vasoactive Peptide Drugs
 Table 5. Key Players of Others
 Table 6. Global Long Chain Modified Peptide Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Long Chain Modified Peptide Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Long Chain Modified Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Long Chain Modified Peptide Drugs Market Share by Region (2020-2025)
 Table 10. Global Long Chain Modified Peptide Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Long Chain Modified Peptide Drugs Market Share by Region (2026-2031)
 Table 12. Long Chain Modified Peptide Drugs Market Trends
 Table 13. Long Chain Modified Peptide Drugs Market Drivers
 Table 14. Long Chain Modified Peptide Drugs Market Challenges
 Table 15. Long Chain Modified Peptide Drugs Market Restraints
 Table 16. Global Long Chain Modified Peptide Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Long Chain Modified Peptide Drugs Market Share by Players (2020-2025)
 Table 18. Global Top Long Chain Modified Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long Chain Modified Peptide Drugs as of 2024)
 Table 19. Ranking of Global Top Long Chain Modified Peptide Drugs Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Long Chain Modified Peptide Drugs Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Long Chain Modified Peptide Drugs, Headquarters and Area Served
 Table 22. Global Key Players of Long Chain Modified Peptide Drugs, Product and Application
 Table 23. Global Key Players of Long Chain Modified Peptide Drugs, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Long Chain Modified Peptide Drugs Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Long Chain Modified Peptide Drugs Revenue Market Share by Type (2020-2025)
 Table 27. Global Long Chain Modified Peptide Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Long Chain Modified Peptide Drugs Revenue Market Share by Type (2026-2031)
 Table 29. Global Long Chain Modified Peptide Drugs Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Long Chain Modified Peptide Drugs Revenue Market Share by Application (2020-2025)
 Table 31. Global Long Chain Modified Peptide Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Long Chain Modified Peptide Drugs Revenue Market Share by Application (2026-2031)
 Table 33. North America Long Chain Modified Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Long Chain Modified Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Long Chain Modified Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Long Chain Modified Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Long Chain Modified Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Long Chain Modified Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Long Chain Modified Peptide Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Long Chain Modified Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Long Chain Modified Peptide Drugs Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Long Chain Modified Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Long Chain Modified Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Long Chain Modified Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Long Chain Modified Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Long Chain Modified Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Long Chain Modified Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Novartis Company Details
 Table 49. Novartis Business Overview
 Table 50. Novartis Long Chain Modified Peptide Drugs Product
 Table 51. Novartis Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
 Table 52. Novartis Recent Development
 Table 53. Merck Serono Company Details
 Table 54. Merck Serono Business Overview
 Table 55. Merck Serono Long Chain Modified Peptide Drugs Product
 Table 56. Merck Serono Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
 Table 57. Merck Serono Recent Development
 Table 58. Ferring Pharmaceuticals Company Details
 Table 59. Ferring Pharmaceuticals Business Overview
 Table 60. Ferring Pharmaceuticals Long Chain Modified Peptide Drugs Product
 Table 61. Ferring Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
 Table 62. Ferring Pharmaceuticals Recent Development
 Table 63. lpsen PHarma Biotech Company Details
 Table 64. lpsen PHarma Biotech Business Overview
 Table 65. lpsen PHarma Biotech Long Chain Modified Peptide Drugs Product
 Table 66. lpsen PHarma Biotech Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
 Table 67. lpsen PHarma Biotech Recent Development
 Table 68. Lilly Company Details
 Table 69. Lilly Business Overview
 Table 70. Lilly Long Chain Modified Peptide Drugs Product
 Table 71. Lilly Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
 Table 72. Lilly Recent Development
 Table 73. AstraZeneca Company Details
 Table 74. AstraZeneca Business Overview
 Table 75. AstraZeneca Long Chain Modified Peptide Drugs Product
 Table 76. AstraZeneca Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
 Table 77. AstraZeneca Recent Development
 Table 78. SciClone Pharmaceuticals Company Details
 Table 79. SciClone Pharmaceuticals Business Overview
 Table 80. SciClone Pharmaceuticals Long Chain Modified Peptide Drugs Product
 Table 81. SciClone Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
 Table 82. SciClone Pharmaceuticals Recent Development
 Table 83. Sinopep Allsino Bio Pharmaceutical Company Details
 Table 84. Sinopep Allsino Bio Pharmaceutical Business Overview
 Table 85. Sinopep Allsino Bio Pharmaceutical Long Chain Modified Peptide Drugs Product
 Table 86. Sinopep Allsino Bio Pharmaceutical Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
 Table 87. Sinopep Allsino Bio Pharmaceutical Recent Development
 Table 88. Takeda Company Details
 Table 89. Takeda Business Overview
 Table 90. Takeda Long Chain Modified Peptide Drugs Product
 Table 91. Takeda Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
 Table 92. Takeda Recent Development
 Table 93. Roche Company Details
 Table 94. Roche Business Overview
 Table 95. Roche Long Chain Modified Peptide Drugs Product
 Table 96. Roche Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
 Table 97. Roche Recent Development
 Table 98. Sanofi Company Details
 Table 99. Sanofi Business Overview
 Table 100. Sanofi Long Chain Modified Peptide Drugs Product
 Table 101. Sanofi Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
 Table 102. Sanofi Recent Development
 Table 103. Ambio Pharmaceuticals Company Details
 Table 104. Ambio Pharmaceuticals Business Overview
 Table 105. Ambio Pharmaceuticals Long Chain Modified Peptide Drugs Product
 Table 106. Ambio Pharmaceuticals Revenue in Long Chain Modified Peptide Drugs Business (2020-2025) & (US$ Million)
 Table 107. Ambio Pharmaceuticals Recent Development
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources
 Table 111. Authors List of This Report


List of Figures
 Figure 1. Long Chain Modified Peptide Drugs Picture
 Figure 2. Global Long Chain Modified Peptide Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Long Chain Modified Peptide Drugs Market Share by Type: 2024 VS 2031
 Figure 4. Hormone Peptide Drugs Features
 Figure 5. Immunomodulatory Peptide Drugs Features
 Figure 6. Vasoactive Peptide Drugs Features
 Figure 7. Others Features
 Figure 8. Global Long Chain Modified Peptide Drugs Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Long Chain Modified Peptide Drugs Market Share by Application: 2024 VS 2031
 Figure 10. Intravenous Injection Case Studies
 Figure 11. Intramuscular Injection Case Studies
 Figure 12. Hypodermic Injection Case Studies
 Figure 13. Others Case Studies
 Figure 14. Long Chain Modified Peptide Drugs Report Years Considered
 Figure 15. Global Long Chain Modified Peptide Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 16. Global Long Chain Modified Peptide Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Long Chain Modified Peptide Drugs Market Share by Region: 2024 VS 2031
 Figure 18. Global Long Chain Modified Peptide Drugs Market Share by Players in 2024
 Figure 19. Global Top Long Chain Modified Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long Chain Modified Peptide Drugs as of 2024)
 Figure 20. The Top 10 and 5 Players Market Share by Long Chain Modified Peptide Drugs Revenue in 2024
 Figure 21. North America Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. North America Long Chain Modified Peptide Drugs Market Share by Country (2020-2031)
 Figure 23. United States Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Canada Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Long Chain Modified Peptide Drugs Market Share by Country (2020-2031)
 Figure 27. Germany Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Nordic Countries Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Long Chain Modified Peptide Drugs Market Share by Region (2020-2031)
 Figure 35. China Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Japan Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. South Korea Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Southeast Asia Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. India Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Australia Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Long Chain Modified Peptide Drugs Market Share by Country (2020-2031)
 Figure 43. Mexico Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Brazil Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Long Chain Modified Peptide Drugs Market Share by Country (2020-2031)
 Figure 47. Turkey Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. UAE Long Chain Modified Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Novartis Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
 Figure 51. Merck Serono Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
 Figure 52. Ferring Pharmaceuticals Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
 Figure 53. lpsen PHarma Biotech Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
 Figure 54. Lilly Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
 Figure 55. AstraZeneca Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
 Figure 56. SciClone Pharmaceuticals Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
 Figure 57. Sinopep Allsino Bio Pharmaceutical Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
 Figure 58. Takeda Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
 Figure 59. Roche Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
 Figure 60. Sanofi Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
 Figure 61. Ambio Pharmaceuticals Revenue Growth Rate in Long Chain Modified Peptide Drugs Business (2020-2025)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Peptide Modification Service Market Research Report 2024
Global Endogenous Peptide Substances Market Research Report 2024
Global Peptide Antibiotics Market Research Report 2025
Global Peptide API Market Research Report 2024
Global High Pure Peptides Market Research Report 2025
Global Oral Peptide Therapeutics Market Research Report 2024
Global Cyclic Peptide Compounds Market Research Report 2024
Therapeutic Peptide Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Peptide Analysis Market Research Report 2025
Global GMP Grade Peptide Market Research Report 2024
Global Peptide Screening Service Market Research Report 2025
Global Long Chain Polyamide Market Research Report 2024
Peptide Drug Conjugates Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Peptides Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Constrained Peptide Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Peptide Health Products Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Peptide Purification System Market Research Report 2024
Global Bicyclic Peptide Drugs Market Research Report 2024
Global Silk Peptide Market Research Report 2024
Peptide CDMO Pharmaceutical Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions